Ambit Biosciences Corp
AMBI
AMBI was delisted on the 10th of November, 2014.
35 hedge funds and large institutions have $79.3M invested in Ambit Biosciences Corp in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 5 closing their positions.
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
52% more funds holding
Funds holding: 23 → 35 (+12)
4% more capital invested
Capital invested by funds: $76M → $79.3M (+$3.37M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$7.29M |
| 2 |
AG
Artal Group
Luxembourg
|
+$3.34M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.55M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.14M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$868K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.01M |
| 2 |
Millennium Management
New York
|
-$1.56M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.54M |
| 4 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$900K |
| 5 |
FM
Forward Management
San Francisco,
California
|
-$177K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $37K | +$54.2K | +4,057 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $15K | +$5.09K | +381 | +31% |
|
28
Citigroup
New York
| $10K | +$13.4K | +1,000 | New |
|
|
U
29
UBS
Zurich,
Switzerland
| $7K | +$5.45K | +408 | +116% |
|
|
BJ
30
BlackRock Japan
Tokyo,
Japan
| $3K | -$7.57K | -567 | -65% |
|
|
MTIP
31
Magee Thomson Investment Partners
San Diego,
California
| $3K | +$3.89K | +291 | New |
|
32
AllianceBernstein
Nashville,
Tennessee
| $1K | – | – | – |
|
33
Bank of America
Charlotte,
North Carolina
| $1K | +$841 | +63 | New |
|
|
34
Millennium Management
New York
| – | -$1.56M | -100,810 | Closed |
|
|
EI
35
EAM Investors
Solana Beach,
California
| – | -$1.54M | -99,447 | Closed |
|
|
FM
36
Forward Management
San Francisco,
California
| – | -$177K | -24,615 | Closed |
|
|
BG
37
BlackRock Group
London,
United Kingdom
| – | -$42K | -2,682 | Closed |
|
|
GH
38
GAM Holding
Zurich,
Switzerland
| – | -$25K | -1,643 | Closed |
|
|
GC
39
Globeflex Capital
San Diego,
California
| – | +$1.07K | +80 | New |
|
AMBI Hedge Fund Activity: Q4 2013 in Review
35 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Ambit Biosciences Corp (AMBI) for Q4 2013, worth a combined $79.3M — up 4.4% from $76M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AMBI positions and 5 closed out — a net gain of 12 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $7.29M. The largest seller was Great Point Partners, cutting an estimated $2.01M.
- 35 institutional investors held Ambit Biosciences Corp (AMBI) as of Q4 2013, up from 23 in Q3 2013.
- Funds reported $79.3M of Ambit Biosciences Corp stock for Q4 2013, up 4.4% quarter-over-quarter.
- 17 funds opened new Ambit Biosciences Corp positions in Q4 2013 and 5 closed out, a net change of +12 holders.
- The largest Ambit Biosciences Corp buyer in Q4 2013 was Redmile Group, an estimated $7.29M added.
- The largest Ambit Biosciences Corp seller in Q4 2013 was Great Point Partners, an estimated $2.01M sold.
Based on aggregated 13F filings for Q4 2013.